Siponimod

Siponimod
Clinical data
Trade namesMayzent[1]
Other namesBAF-312
AHFS/Drugs.comMonograph
MedlinePlusa619027
License data
Pregnancy
category
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
  • 1-({4-[(1E)-1-({[4-Cyclohexyl- 3-(trifluoromethyl)phenyl]methoxy}imino)ethyl]-2-ethylphenyl}methyl)azetidine-3-carboxylic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC29H35F3N2O3
Molar mass516.605 g·mol−1
3D model (JSmol)
  • CCC1=C(C=CC(=C1)C(=NOCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)C)CN4CC(C4)C(=O)O
  • InChI=1S/C29H35F3N2O3/c1-3-21-14-23(10-11-24(21)15-34-16-25(17-34)28(35)36)19(2)33-37-18-20-9-12-26(22-7-5-4-6-8-22)27(13-20)29(30,31)32/h9-14,22,25H,3-8,15-18H2,1-2H3,(H,35,36)/b33-19+
  • Key:KIHYPELVXPAIDH-HNSNBQBZSA-N

Siponimod, sold under the brand name Mayzent, is a selective sphingosine-1-phosphate receptor modulator for oral use that is used for multiple sclerosis (MS).[8] It is intended for once-daily oral administration.[10][8]

In March 2019, it was approved in the United States to treat adults with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.[1]

  1. ^ a b "FDA approves new oral drug to treat multiple sclerosis". U.S. Food and Drug Administration (FDA) (Press release). 26 March 2019. Archived from the original on 27 November 2019. Retrieved 24 November 2019.Public Domain This article incorporates text from this source, which is in the public domain.
  2. ^ "Mayzent Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 13 December 2019. Retrieved 23 August 2020.
  3. ^ "Summary for ARTG Entry:310499 Mayzent siponimod 2 mg film-coated tablet blister pack" (PDF). Therapeutic Goods Administration (TGA). Retrieved 23 August 2020.[permanent dead link]
  4. ^ "Australian Public Assessment Report for Siponimod" (PDF). Therapeutic Goods Administration (TGA).
  5. ^ "Mayzent Product information". Health Canada. Retrieved 29 May 2022.
  6. ^ "Summary Basis of Decision (SBD) for Mayzent". Health Canada. 23 October 2014. Retrieved 29 May 2022.
  7. ^ "Mayzent 2 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 24 April 2020. Retrieved 23 August 2020.
  8. ^ a b c "Mayzent- siponimod tablet, film coated". DailyMed. 26 March 2019. Retrieved 22 January 2020.
  9. ^ Cite error: The named reference Mayzent EPAR was invoked but never defined (see the help page).
  10. ^ Kappos L, Bar-Or A, Cree B, Fox R, Giovannoni G, Gold R, et al. (2014). "Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis: Design of the phase 3 EXPAND trial". Multiple Sclerosis and Related Disorders. 3 (6): 752. doi:10.1016/j.msard.2014.09.185. ISSN 2211-0348.